Differences in failure patterns according to the EGFR mutation status after proton beam therapy for early stage non-small cell lung cancer.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 32387485.
- Also identified by DOI 10.1016/j.radonc.2020.04.056.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We analyzed 135 patients (including 27 EGFR-mutant and 29 EGFR-wild) with T1-3N0M0 non-squamous NSCLC treated by PBT. Considering the 3-year cumulative incidence, the EGFR-mutant group showed a significantly lower infield failure rate (9% vs 27%, p = 0.02) and higher out-of-field failure rate (67% vs 40%, p = 0.02) than the EGFR-wild group.
Medical subject headings
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- Proton Therapy